Ohcanbohtosat - Sara Santagostino

First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers Dahkki Fei Tang, Rebecca Kunder, Tom Chu, Avis Hains, Allen Nguyen, Jacqueline M. McBride, Yu Zhong, Sara Santagostino, Maria Wilson, Abigail Trenchak, Liuxi Chen, Justin Ly, Anita Moein, Nicholas Lewin‐Koh, Vibha Raghavan, Uyi Osaghae, Chris Wynne, Ryan Owen, David Place

Connect to this object online.